MXC - MGC Pharmaceuticals makes good progress with CimetrA and CannEpil treatments
(NewsDirect)
MGC Pharmaceuticals chief commercialofficer Robert Clements joined Proactive's Stephen Gunnion withdetails of the company's activity in the first quarter of 2023, aswell as upcoming milestones.
Clements noted that clinical trials of its CimetrA drug continueto demonstrate anti-inflammatory effects, with the results set to beused in a US new drug submission, adding that the US market holdssignificant potential for the company.
This year, he said the company will also focus on expandingaccess to CannEpil in Europe, and advancing its cannabinoid-basedinvestigational products.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.